Related Articles
Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of scheduling
A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients
Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death
ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel